PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Chemically synthesized ligands for nuclear receptors of the PPAR family modulate a number of physiological functions, particularly insulin resistance in the context of energy homeostasis and the metabolic syndrome. Additionally, these compounds may treat or prevent the development of many secondary...

Full description

Bibliographic Details
Main Author:	Ancha Baranova
Format:	Article
Language:	English
Published:	Hindawi Limited 2008-01-01
Series:	PPAR Research
Online Access:	http://dx.doi.org/10.1155/2008/230893

Similar Items

Synthesis of Phthalimide Derivatives as Potential PPAR-γ Ligands
by: So Hyeon Eom, et al.
Published: (2016-06-01)

PPAR Ligands for Cancer Chemoprevention
by: Yumiko Yasui, et al.
Published: (2008-01-01)

Nutraceuticals as Ligands of PPARγ
by: Meera Penumetcha, et al.
Published: (2012-01-01)

Natural and Synthetic PPARγ Ligands in Tumor Microenvironment: A New Potential Strategy against Breast Cancer
by: Giuseppina Augimeri, et al.
Published: (2020-12-01)

Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPARγ Ligands as a Potential Target in Breast Cancer
by: Giulia Gionfriddo, et al.
Published: (2020-01-01)

Effects of PPARγ Ligands on Leukemia
by: Yoko Tabe, et al.
Published: (2012-01-01)

The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies
by: Giuseppina Augimeri, et al.
Published: (2020-09-01)

The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination
by: Graham Skelhorne-Gross, et al.
Published: (2012-01-01)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
by: Ajit A. Kulkarni, et al.
Published: (2012-01-01)

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
by: Ambra Pozzi, et al.
Published: (2008-01-01)

Clinical Use of PPARγ Ligands in Cancer
by: Jennifer L. Hatton, et al.
Published: (2008-01-01)

PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors
by: Elisabetta Benedetti, et al.
Published: (2010-01-01)

PPAR-γ Ligand Inhibits Nasopharyngeal Carcinoma Cell Proliferation and Metastasis by Regulating E2F2
by: Ping-Li Yang, et al.
Published: (2019-01-01)

A ligand of peroxisome-proliferator activated receptor #gamma# (PPAR#gamm#), has potential in the treatment of neuroblastoma
by: Rodway, Helen Anne
Published: (2002)

PPARα/γ-Independent Effects of PPARα/γ Ligands on Cysteinyl Leukotriene Production in Mast Cells
by: Masamichi Yamashita
Published: (2008-01-01)

Synergistic Effects of PPARγ Ligands and Retinoids in Cancer Treatment
by: Masahito Shimizu, et al.
Published: (2008-01-01)

Corrigendum to “PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors”
by: Elisabetta Benedetti, et al.
Published: (2019-01-01)

Study of the Effects of PPAR-γ Ligand on MAP Kinase and Cyclooxygenase in Human Lung Carcinoma Cell Line A549
by: Yu-wei Chou, et al.
Published: (2007)

Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases
by: Jens Tiefenbach, et al.
Published: (2018-09-01)

Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ
by: Jinsai Shang, et al.
Published: (2018-12-01)

PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1
by: Shibo Ying, et al.
Published: (2016-01-01)

Identification of PPARγ ligands with One-dimensional Drug Profile Matching
by: Kov&aacute;cs D, et al.
Published: (2013-09-01)

TNFRSF12A and CD38 Contribute to a Vicious Circle for Chronic Obstructive Pulmonary Disease by Engaging Senescence Pathways
by: Yan Dong, et al.
Published: (2020-05-01)

Characterizing the Binding Potential, Activity, and Bioaccessibility of Peroxisome Proliferator Activated Receptor Gamma (PPARγ) Ligands in Indoor Dust
by: FANG, MINGLIANG
Published: (2015)

PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma
by: Osamu Kimura, et al.
Published: (2012-01-01)

Anti-aging dilemma: to restore the hardware or to reinstall the software?
by: Ancha eBaranova, et al.
Published: (2015-04-01)

Peroxisome Proliferator Activator Receptor (PPAR)-γ Ligand, but Not PPAR-α, Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver
by: Azza A. K. El-Sheikh, et al.
Published: (2014-01-01)

PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates
by: Shotaro Kamata, et al.
Published: (2020-11-01)

Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors
by: Leonardo Brunetti, et al.
Published: (2020-09-01)

Hydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs[S]
by: Hidetoshi Yamada, et al.
Published: (2014-05-01)

Study of the inhibitory effects of PPAR ligands on the TGF-beta-induced liver fibrosis.
by: Ching-Ju Cheng, et al.
Published: (2006)

Identification of a Potential PPAR-Related Multigene Signature Predicting Prognosis of Patients with Hepatocellular Carcinoma
by: Wenfang Xu, et al.
Published: (2021-01-01)

Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis
by: Ivan V. Shirinsky, et al.
Published: (2011-01-01)

Clinicopathological Significance of PPARγ in Hepatocellular Carcinoma and PPARγ-Mediated Suppression of Growth, Migration, and Angiogenesis in Human Hepatocellular Carcinoma Cells
by: Hui-Tzu Hsu, et al.
Published: (2017)

A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients
by: Leonid Gozman, et al.
Published: (2021-09-01)

Comprehensive Analysis of Human microRNA–mRNA Interactome
by: Olga Plotnikova, et al.
Published: (2019-10-01)

Unraveling Risk Genes of COVID-19 by Multi-Omics Integrative Analyses
by: Ancha Baranova, et al.
Published: (2021-09-01)

COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ
by: Wiley Elizabeth L, et al.
Published: (2008-01-01)

MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
by: Xu Wang, et al.
Published: (2017-09-01)

The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products
by: Mario Umberto Dianzani, et al.
Published: (2008-01-01)